SAI LIFE SCIENCES Latest Share Price (SAILIFE)
TODAY IN ONE LINE
SAILIFE dropped 3.6% on average volume, lagging Nifty's -1.6% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹31,947.7 Cr., it trades at a P/E of 87.85. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SAI LIFE SCIENCES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 17.6% YoY
- ●Healthy Operating MarginsOPM is structurally strong at 22.7%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.04x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 1.4% YoY
- ●Expensive ValuationTrading at a high P/E ratio of 75.2x
- ●FII SellingFII holding decreased by 1.52% QoQ
- ●Rising Receivables vs SalesReceivables grew 33.7% outpacing sales growth of 15.7%
Latest SAI LIFE SCIENCES News
What changed recently?
Recent events, corporate actions, and announcements.
SAI LIFE SCIENCES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SAI LIFE SCIENCES, framed against the sector median so the premium or discount is obvious at a glance.
SAI LIFE SCIENCES trades at a P/E of 87.85× and P/B of 12.82×, against the Healthcare sector median P/E of 45.09×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SAI LIFE SCIENCES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SAI LIFE SCIENCES — derived from the latest tape, not yesterday's close.
SAI LIFE SCIENCES last traded at ₹1,505.6 with an intraday range of ₹1,499–₹1,563.4 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1505.60| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1675.13 | +169.53 | +11.26% |
| R3 | 1610.73 | +105.13 | +6.98% |
| R2 | 1587.07 | +81.47 | +5.41% |
| R1 | 1546.33 | +40.73 | +2.71% |
| PIVOT | 1522.67 | 17.07 | 1.13% |
| CURRENT | 1505.60 | — | — |
| S1 | 1481.93 | -23.67 | -1.57% |
| S2 | 1458.27 | -47.33 | -3.14% |
| S3 | 1417.53 | -88.07 | -5.85% |
| S4 | 1353.13 | -152.47 | -10.13% |
SAILIFE is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1524–₹1563.4
Trading Below opening range, showing Bearishness
SAI LIFE SCIENCES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SAI LIFE SCIENCES — consolidated or standalone — with margins, YoY growth and key ratios inline.
SAI LIFE SCIENCES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹31,947.7 Cr. and reported EPS of ₹3.36.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,695 | 2,192 ▲ 29.4% |
| Sales Growth YoY %Derived | — | 29.38% |
| Other Income | 37 | 49 ▲ 33.6% |
| Total Income | 1,731 | 2,242 ▲ 29.5% |
| 466 | 571 ▲ 22.6% | |
| Gross ProfitDerived | 1,229 | 1,622 ▲ 32.0% |
| Gross Margin %Derived | 72.51% | 73.96% |
| 823 | 990 ▲ 20.3% | |
| EBITDA (Operating Profit)Derived | 406 | 631 ▲ 55.6% |
| OPM %Derived | 23.94% | 28.79% |
| 215 | 198 ▼ 7.8% | |
| Profit Before Tax (PBT) | 228 | 466 ▲ 104.7% |
| 58 | 117 ▲ 103.7% | |
| Effective Tax %Derived | 25.28% | 25.16% |
| Total Profit for Period | 170 | 349 ▲ 105.1% |
| Net Profit (Owner's PAT)Derived | 170 | 349 ▲ 105.1% |
| Net Profit Margin %Derived | 10.04% | 15.91% |
| PAT Growth YoY %Derived | — | 105.08% |
| Earnings Per Share (EPS ₹) | 8.16 | 16.48 ▲ 102.0% |
| Diluted Shares Outstanding (Cr) | 21 | 21 ▲ 1.6% |
| Other Comprehensive Income (Net of Tax) | 1 | -21 ▼ 1851.2% |
| Total Expenses (incl. D&A & Interest) | 1,504 | 1,775 ▲ 18.1% |
| Material Cost % of RevenueDerived | 27.19% | 26.37% |
| Employee Cost % of RevenueDerived | 32.40% | 31.15% |
| Other Cost % of RevenueDerived | 16.17% | 14.02% |
| Interest Coverage (x)Derived | 3.51x | 11.83x |
| Period | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|
| Revenue from Operations | 1,695 | 2,192 ▲ 29.4% | |
| Sales Growth YoY %Derived | — | 29.38% | |
| Other Income | 37 | 49 ▲ 33.6% | |
| Total Income | 1,731 | 2,242 ▲ 29.5% | |
466 | 571 ▲ 22.6% | ||
| Gross ProfitDerived | 1,229 | 1,622 ▲ 32.0% | |
| Gross Margin %Derived | 72.51% | 73.96% | |
823 | 990 ▲ 20.3% | ||
| EBITDA (Operating Profit)Derived | 406 | 631 ▲ 55.6% | |
| OPM %Derived | 23.94% | 28.79% | |
215 | 198 ▼ 7.8% | ||
| Profit Before Tax (PBT) | 228 | 466 ▲ 104.7% | |
58 | 117 ▲ 103.7% | ||
| Effective Tax %Derived | 25.28% | 25.16% | |
| Total Profit for Period | 170 | 349 ▲ 105.1% | |
| Net Profit (Owner's PAT)Derived | 170 | 349 ▲ 105.1% | |
| Net Profit Margin %Derived | 10.04% | 15.91% | |
| PAT Growth YoY %Derived | — | 105.08% | |
| Earnings Per Share (EPS ₹) | 8.16 | 16.48 ▲ 102.0% | |
| Diluted Shares Outstanding (Cr) | 21 | 21 ▲ 1.6% | |
| Other Comprehensive Income (Net of Tax) | 1 | -21 ▼ 1851.2% | |
| Total Expenses (incl. D&A & Interest) | 1,504 | 1,775 ▲ 18.1% | |
| Material Cost % of RevenueDerived | 27.19% | 26.37% | |
| Employee Cost % of RevenueDerived | 32.40% | 31.15% | |
| Other Cost % of RevenueDerived | 16.17% | 14.02% | |
| Interest Coverage (x)Derived | 3.51x | 11.83x |
SAI LIFE SCIENCES segment analysis : revenue and profit mix.
Disclosed business segments at SAI LIFE SCIENCES with their share of revenue and profit, switchable between consolidated and standalone reporting.
SAI LIFE SCIENCES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SAI LIFE SCIENCES.
Our AI distills the core fundamental drivers supporting SAI LIFE SCIENCES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
SAI LIFE SCIENCES's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 114 (~2.5× the sector multiple of 45.1) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 9% would indicate weaker capital compounding.
SAI LIFE SCIENCES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SAI LIFE SCIENCES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SAI LIFE SCIENCES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SAI LIFE SCIENCES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SAI LIFE SCIENCES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SAI LIFE SCIENCES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SAI LIFE SCIENCES stood at 56.5% of traded volume, against a 20-day average of 52.6%.
SAI LIFE SCIENCES announcements: results, concalls, ratings, M&A.
Filings SAI LIFE SCIENCES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SAI LIFE SCIENCES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 220 documents below.
Trading Window
Sai Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Allotment of Securities
Sai Life Sciences Limited has informed the Exchange regarding allotment of 24000 securities pursuant to ESOP/ESPS at its meeting held on September…
Shareholders meeting
Sai Life Sciences Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 17, 2026. Further, the…
Shareholders meeting
Sai Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 17, 2026
Analysts/Institutional Investor Meet/Con. Call Updates
Sai Life Sciences Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
SAI LIFE SCIENCES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SAI LIFE SCIENCES has declared, sequenced by announce and record date.
SAI LIFE SCIENCES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
SAI LIFE SCIENCES insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in SAI LIFE SCIENCES as reported to SEBI — buying and selling signals from the people who know the business best.
SAI LIFE SCIENCES insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| TUNER GHOSH | Insider | 21 Feb 2025 | sell | −71.1 K | ₹5.07 Cr. | ₹713.07 |
About SAI LIFE SCIENCES: business, sector, key facts.
What SAI LIFE SCIENCES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SAI LIFE SCIENCES operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SAILIFE, BSE: 544306.
Sai Life Sciences Limited is a prominent Contract Research, Development, and Manufacturing Organization (CRDMO) with a global reach, headquartered in Hyderabad, India. Established in 1999 (and formerly known as SAI Advantium Pharma Limited until 2006), the company provides a comprehensive suite of services across the entire drug development lifecycle, from initial research to final manufacturing.
The core business of Sai Life Sciences centers around offering a wide range of services to pharmaceutical and biotechnology companies. These services encompass crucial aspects of drug development and production. Their expertise lies in medicinal chemistry, a critical area for designing and synthesizing new drug molecules. They also possess significant capabilities in pharmacokinetics (PK), the study of how drugs are absorbed, distributed, metabolized, and excreted by the body, which is crucial for determining optimal dosage and safety profiles.
Furthermore, Sai Life Sciences plays a vital role in the manufacturing process, handling the large-scale production of active pharmaceutical ingredients (APIs) and other drug substances. This aspect is crucial for bringing new medicines to the market. In addition to manufacturing, the company offers contract development services, assisting clients with the intricate process of developing their drugs from the laboratory to commercial production. This includes process development, analytical method development and validation, and regulatory support.
In essence, Sai Life Sciences acts as a comprehensive partner for pharmaceutical and biotechnology firms, offering a one-stop solution for many of their research, development, and manufacturing needs. This integrated approach allows clients to streamline their operations, reduce costs, and accelerate the development and launch of new drugs. Their broad service offering and global presence position them as a key player in the contract research and manufacturing landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about SAI LIFE SCIENCES (SAILIFE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SAI LIFE SCIENCES (SAILIFE)?
The current share price of SAI LIFE SCIENCES (SAILIFE) is ₹1,505.60. Today, the stock has declined by ₹56.20 (3.6%), trading in a range of ₹1,499.00 to ₹1,563.40. The stock opened at ₹1,563.40 with a trading volume of 5,13,978 shares.
02Is SAI LIFE SCIENCES stock a good investment for long-term?
SAI LIFE SCIENCES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹31,947.7 Cr., P/E ratio of 87.85, ROE of 13.62%, and ROCE of 14.49%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SAI LIFE SCIENCES stock?
The 52-week high price of SAI LIFE SCIENCES (SAILIFE) is ₹1,697.00, while the 52-week low is ₹783.85. Currently trading at ₹1,505.60, the stock is 92.08% above its 52-week low and 11.28% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SAI LIFE SCIENCES stock at the current price?
Whether to buy SAI LIFE SCIENCES stock at ₹1,505.60 depends on multiple factors. The stock is currently trading with a P/E ratio of 87.85 and P/B ratio of 12.82. Today's performance shows a loss of 3.6%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SAI LIFE SCIENCES and when is the next dividend?
SAI LIFE SCIENCES offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹1,505.60, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of SAI LIFE SCIENCES?
SAI LIFE SCIENCES's key financial metrics include: P/E Ratio: 87.85, P/B Ratio: 12.82, ROE: 13.62%, ROCE: 14.49%, Dividend Yield: 0%, EPS: ₹3.36, Book Value: ₹117.00, and Debt-to-Equity: 0.04. The company's market cap stands at ₹31,947.7 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is SAI LIFE SCIENCES stock performing today in the market?
SAI LIFE SCIENCES stock opened at ₹1,563.40 and is currently trading at ₹1,505.60, showing a decline of ₹56.20 (3.6%). The intraday high is ₹1,563.40 and low is ₹1,499.00. The trading volume stands at 5,13,978 shares, indicating moderate market participation today.
08What is the P/E ratio of SAI LIFE SCIENCES and what does it indicate?
SAI LIFE SCIENCES has a Price-to-Earnings (P/E) ratio of 87.85, which means investors are willing to pay 87.85 for every ₹1 of earnings. With an EPS of ₹3.36, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about SAI LIFE SCIENCES (SAILIFE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.